Prostate Cancer MDx Firm GenomeDx to Launch First Test This Year | GenomeWeb

NEW YORK (GenomeWeb News) – Seeking a share of a market estimated at around $1 billion, GenomeDx plans to launch its first test aimed at prostate cancer during the first half of this year, CEO Doug Dolginow said.

Based on whole-genome analysis to profile RNA expression signatures, the test measures the aggressiveness of prostate cancer in patients who have had a prostatectomy. Typically, after the surgery, a doctor will monitor a patient's prostate-specific antigen levels to evaluate whether the cancer has returned and whether follow-up treatment is needed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.